Midday movers: Lowe's and Zoom rise; Unity Software falls

Go back to Midday movers: Lowe's and Zoom rise; Unity Software falls

TD Cowen Downgrades Macy's (M) to Market Perform, 'Prudent Bold New Changes Will Take Time to Drive Upside to Guidance'

February 29, 2024 5:29 AM UTC

TD Cowen analyst Oliver Chen downgraded Macy's (NYSE: M) from Outperform to Market Perform with a price target of $20.00 (from $23.00).

The analyst comments "We like changes ahead including 150 Macy's closures, store growth across luxury (+30 Bluemercury & +15 Bloomies) and small format (+30), and private label and inventory... More

Macy's (M) PT Raised to $22 at Citi, 'We Lean More Positive but Stay Neutral'

February 28, 2024 3:19 AM UTC

Citi analyst Paul Lejuez raised the price target on Macy's (NYSE: M) to $22.00 (from $18.00) while maintaining a Neutral rating.

The analyst comments "4Q GM/EPS beat consensus though sales were still weak (comps -5%) and mgmt is looking for a sales decline in... More

CFRA Downgrades Macy's (M) to Hold

February 27, 2024 12:55 PM UTC

CFRA analyst Zachary Warring downgraded Macy's (NYSE: M) from Buy to Hold with a price target of $18.00 (from $19.00).

The analyst comments "We lower our 12-month price target by $1 to $18, based on 7.2x our FY 25 (Jan.) EPS estimate and in line with the company's... More

Viking Therapeutic (VKTX) PT Raised to $80 at Stifel, '“Best-in-Class” Profile of Injectable VK2735 Stands Firm'

February 27, 2024 12:06 PM UTC

Stifel analyst Samimy Annabel raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $80.00 (from $35.00) while maintaining a Buy rating.

The analyst comments "Ahead of schedule, VKTX released the Ph.2 VENTURE data for injectable-VK2735, which again demonstrated a highly competitive profile relative to... More

AutoZone (AZO) PT Raised to $3,200 at CFRA, 'We...like AZO's robust international growth'

February 27, 2024 12:04 PM UTC

CFRA analyst Garrett Nelson raised the price target on AutoZone (NYSE: AZO) to $3,200.00 (from $3,000.00) while maintaining a Buy rating.

The analyst comments "We lift our 12-month target to $3,200 from $3,000, based on a FY 25 (Aug.) P/E of 19.0x, a premium to... More